Tumour inhibition by interleukin-2 at the tumour/host interface

This publication has 74 references indexed in Scilit:

• Interferon‐activated tumor inhibition in vivo. Small amounts of interferon‐gamma inhibit tumor growth by eliciting host systemic immunoreactivity
  International Journal of Cancer, 1986
• Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
  New England Journal of Medicine, 1985
• Synthesis and secretion of eosinophil granule substances
  Immunology Today, 1985
• Antitumor reactivity in vitro and in vivo of lymphocytes from normal donors and cancer patients propagated in culture with T cell growth factor (TCGF)
  European Journal of Cancer and Clinical Oncology, 1983
• In vitro detection of cell‐mediated immunity to individual tumor‐specific antigens of chemically induced BALB/c fibrosarcomas
  International Journal of Cancer, 1983
• Immune recognition of tumor cells in vivo. I. Role of H‐2 gene products in T lymphocyte activation against minor histocompatibility antigens displayed by adenocarcinoma cells
  European Journal of Immunology, 1982
• Clearance of interleukin 2 from the blood of normal and T cell‐depleted mice
  European Journal of Immunology, 1982
• T-cell-derived helper factor allows in vivo induction of cytotoxic T cells in nu/nu mice
  Nature, 1980
• Continuous culture of T cells cytotoxic for autologous human leukaemia cells
  Nature, 1979
• Cell-mediated immunity to antigens associated with murine sarcoma virus-induced tumors: augmentation of cytolytic T lymphocyte activity by successive specific and nonspecific stimulationin vitro
  European Journal of Immunology, 1979